Loading filters...
Publications per Year (1639 total)
27
1990
44
·
53
·
46
·
56
·
41
1995
52
·
46
·
2
·
41
·
43
2000
50
·
47
·
66
·
2
·
41
2005
51
·
2
·
1
·
2
·
3
2010
7
·
33
·
64
·
58
·
58
2015
61
·
73
·
74
·
68
·
69
2020
85
·
53
·
64
·
59
·
70
2025
27
·
Loaded
Click to load
50 / 1639 papers loaded(scroll for more)
202613 papers
BRAF V600Early (I-II)2026
Updates in adjuvant and neoadjuvant therapies for resectable cutaneous melanoma.
Hadfield MJ et al. J Am Acad Dermatol. 2026
BRAF V600Early (I-II)2026
Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3.
Devoldere A et al. Melanoma Res. 2026
BRAF V600advanced2026
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.
Dummer R et al. Clin Cancer Res. 2026
Uvealadvanced2026
Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.
Kissinger CR et al. Melanoma Res. 2026
Immunotherapyadvanced2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
Albrecht LJ et al. Eur J Cancer. 2026
ImmunotherapyEarly (I-II)2026
Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands.
Wilson MJ et al. Eur J Cancer. 2026
cytokineAll Stages2026
Intralesional Interleukin-2 Therapy for Treatment of Cutaneous Squamous Cell Carcinoma.
Giacomantonio CA et al. JAMA Dermatol. 2026
BRAF V600All Stages2026
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanoma.
Namir G et al. Melanoma Res. 2026
cytokineadvanced2026
Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance.
Haist M et al. Cancer Cell. 2026
Uvealadvanced2026
Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma.
Yang K et al. Melanoma Res. 2026
Uvealadvanced2026
Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.
Ramelyte E et al. Clin Cancer Res. 2026
Immunotherapyadvanced2026
Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.
van den Hoek L et al. Lancet Oncol. 2026
AdjuvantAll Stages2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.
Dummer R et al. Lancet Oncol. 2026
200636 papers
Generaladvanced2006
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ et al. Eur J Cancer. 2006
GeneralAll Stages2006
The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK et al. Melanoma Res. 2006
Generaladvanced2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY et al. J Clin Oncol. 2006
cytokineadvanced2006
Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
Dummer R et al. J Clin Oncol. 2006
cytokineadvanced2006
Cytokine-based therapy and biochemotherapy for advanced melanoma.
Atkins MB et al. Clin Cancer Res. 2006
cytokineadvanced2006
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
Cesana GC et al. J Clin Oncol. 2006
cytokineEarly (I-II)2006
Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.
Dixon S et al. Br J Cancer. 2006
cytokineadvanced2006
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
Guida M et al. Melanoma Res. 2006
cytokineEarly (I-II)2006
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
Ferrone CR et al. Clin Cancer Res. 2006
cytokineEarly (I-II)2006
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T et al. Cancer Res. 2006
cytokineAll Stages2006
Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
Nishimura F et al. Cancer Res. 2006
cytokineAll Stages2006
Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.
Wankowicz-Kalinska A et al. Melanoma Res. 2006
cytokineadvanced2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL et al. Clin Cancer Res. 2006
Generaladvanced2006
Persistent thrombocytopenia during melanoma treatment with fotemustine.
Turrisi G et al. Melanoma Res. 2006
GeneralAll Stages2006
Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model.
Wolf M et al. Melanoma Res. 2006
Generaladvanced2006
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H et al. Ann Oncol. 2006
cytokineAll Stages2006
Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.
Gottlieb DJ et al. Br J Cancer. 2006
Generaladvanced2006
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.
Ko SH et al. Clin Cancer Res. 2006
GeneralAll Stages2006
Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD et al. Clin Cancer Res. 2006
cytokineadvanced2006
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
Pashenkov M et al. J Clin Oncol. 2006
cytokineadvanced2006
Estrogen receptor-alpha methylation predicts melanoma progression.
Mori T et al. Cancer Res. 2006
Generaladvanced2006
Chemotherapy and targeted therapy combinations in advanced melanoma.
Flaherty KT et al. Clin Cancer Res. 2006
GeneralAll Stages2006
Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.
Schmitt E et al. Cancer Res. 2006
GeneralAll Stages2006
Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR et al. Clin Cancer Res. 2006
GeneralAll Stages2006
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Peters S et al. Ann Oncol. 2006
Generaladvanced2006
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Schadendorf D et al. Ann Oncol. 2006
Generaladvanced2006
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Ron IG et al. Melanoma Res. 2006
GeneralAll Stages2006
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
González Cao M et al. Melanoma Res. 2006
cytokineadvanced2006
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A et al. J Clin Oncol. 2006
cytokineadvanced2006
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA et al. Clin Cancer Res. 2006
cytokineAll Stages2006
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ et al. J Clin Oncol. 2006
cytokineAll Stages2006
Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA et al. Clin Cancer Res. 2006
Generaladvanced2006
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Schadendorf D et al. Ann Oncol. 2006
cytokineAll Stages2006
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
Koyanagi K et al. Cancer Res. 2006
cytokineadvanced2006
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
Lindsey KR et al. Clin Cancer Res. 2006
Generaladvanced2006
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.
Gietema JA et al. Ann Oncol. 2006
20071 papers
Generaladvanced2007
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Larkin JM et al. Br J Cancer. 2007